KDM1A and Ewing sarcoma: The synergy between CFZ and LSD1 inhibition was further confirmed using SP2577 (seclidemstat), a SP2509 analog in clinical trial for advanced solid tumors (NCT03895684) and relapsed/refractory Ewing sarcomas (NCT03600649) [33] (Fig. 4C).